Literature DB >> 26201918

Management of acute kidney injury in cirrhosis.

Suman Lata Nayak1, Rakhi Maiwall2, Ashish Nandwani3, Sivaramakrishnan Ramanarayanan3, R P Mathur3, Ramesh Kumar2, S K Sarin2, Chitranshu Vashishtha2.   

Abstract

Acute kidney injury (AKI) is a relatively frequent problem, occurring in approximately 20 % of hospitalized patients with cirrhosis. Although serum creatinine (S Cr) is the most commonly used method to determine AKI because of easy availability and low cost, practically it underestimates the extent of kidney injury in patients with chronic liver disease. AKI is defined as an abrupt rise in S Cr of 0.3 mg/dl or more (>26.4 mmol/l) or an increase of 150 % or more (1.5-fold) from baseline. The cause of AKI in cirrhosis is multifactorial and is unique in terms of pathogenesis. The most common causes of AKI in cirrhosis can be subdivided into either functional or structural. The functional group includes volume-responsive (prerenal azotemia) and volume-unresponsive states (hepatorenal syndrome). Volume responsive is the most common type of AKI due to frequent use of diuretics, large volume abdominal paracentesis and gastrointestinal bleeding in patients with liver disease. The structural causes include acute tubular necrosis, tubulointerstitial and glomerular diseases. Patients with decompensated cirrhosis are in a vasodilatory state leading to a decrease in effective arterial blood volume, predisposing to AKI. Therefore, management of AKI depends on the underlying cause, and therapy should be directed toward removal of the cause. The outcome in cirrhosis when patients are on dialysis is very dismal. Every effort should be made to prevent AKI.

Entities:  

Keywords:  Acute kidney injury; Acute renal failure; Acute tubular necrosis; Chronic liver disease; Cirrhosis; Hepatorenal syndrome

Year:  2013        PMID: 26201918     DOI: 10.1007/s12072-013-9456-x

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  27 in total

Review 1.  Albumin: biochemical properties and therapeutic potential.

Authors:  Gregory J Quinlan; Greg S Martin; Timothy W Evans
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

Review 2.  Diagnosis and treatment of acute renal failure in patients with cirrhosis.

Authors:  Richard Moreau; Didier Lebrec
Journal:  Best Pract Res Clin Gastroenterol       Date:  2007       Impact factor: 3.043

3.  Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration.

Authors:  Alexander L Gerbes; Elisabeth Huber; Veit Gülberg
Journal:  Gastroenterology       Date:  2009-07-23       Impact factor: 22.682

Review 4.  Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome.

Authors:  Lise L Gluud; Kurt Christensen; Erik Christensen; Aleksander Krag
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

Review 5.  Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.

Authors:  Sashidhar V Sagi; Sahil Mittal; Krishna S Kasturi; Gagan K Sood
Journal:  J Gastroenterol Hepatol       Date:  2010-01-14       Impact factor: 4.029

Review 6.  The hepatorenal syndrome.

Authors:  Santiago J Munoz
Journal:  Med Clin North Am       Date:  2008-07       Impact factor: 5.456

Review 7.  Assessing renal function in cirrhotic patients: problems and pitfalls.

Authors:  Deb S Sherman; Douglas N Fish; Isaac Teitelbaum
Journal:  Am J Kidney Dis       Date:  2003-02       Impact factor: 8.860

8.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

Authors:  Arun J Sanyal; Thomas Boyer; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Andres Blei; Veit Gülberg; Samuel Sigal; Peter Teuber
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

9.  Simultaneous liver-kidney transplantation: evaluation to decision making.

Authors:  C L Davis; S Feng; R Sung; F Wong; N P Goodrich; L B Melton; K R Reddy; M K Guidinger; A Wilkinson; J Lake
Journal:  Am J Transplant       Date:  2007-05-26       Impact factor: 8.086

10.  An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.

Authors:  Praveen Sharma; Ashish Kumar; Brajesh C Shrama; Shiv K Sarin
Journal:  Am J Gastroenterol       Date:  2008-06-28       Impact factor: 10.864

View more
  4 in total

1.  National trends of acute kidney injury requiring dialysis in decompensated cirrhosis hospitalizations in the United States.

Authors:  Girish N Nadkarni; Priya K Simoes; Achint Patel; Shanti Patel; Rabi Yacoub; Ioannis Konstantinidis; Sunil Kamat; Narender Annapureddy; Chirag R Parikh; Steven G Coca
Journal:  Hepatol Int       Date:  2016-01-29       Impact factor: 6.047

Review 2.  Acute kidney injury in children with chronic liver disease.

Authors:  Akash Deep; Romit Saxena; Bipin Jose
Journal:  Pediatr Nephrol       Date:  2018-03-01       Impact factor: 3.714

3.  Sarcopenia is the independent predictor of mortality in critically ill patients with cirrhosis.

Authors:  Saniya Khan; Jaya Benjamin; Rakhi Maiwall; Harshita Tripathi; Puja Bhatia Kapoor; Varsha Shasthry; Vandana Saluja; Prashant Agrawal; Shalini Thapar; Guresh Kumar
Journal:  J Clin Transl Res       Date:  2022-05-25

4.  Identifying critically ill patients with cirrhosis who benefit from nutrition therapy: the mNUTRIC score study.

Authors:  Harshita Tripathi; Jaya Benjamin; Rakhi Maiwall; Puneet Puri; Puja Bhatia Kapoor; Varsha Shasthry; Vandana Saluja; Prashant Agrawal; Guresh Kumar; Yogendra Kumar Joshi; Shiv Kumar Sarin
Journal:  J Clin Transl Res       Date:  2022-09-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.